Crossmark Global Holdings’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Crossmark Global Holdings’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5,428	Closed	-$231K	–	1439
2020 Q3	$231K	Buy	5,428 +180	+3%	+$7.87K	0.01%	1164
2020 Q2	$252K	Buy	5,248 +480	+10%	+$23.9K	0.01%	1111
2020 Q1	$219K	Buy	4,768 +20	+0.4%	+$1K	0.01%	1010
2019 Q4	$285K	Buy	4,748 +230	+5%	+$13.7K	0.01%	1147
2019 Q3	$256K	Buy	4,518 +40	+0.9%	+$2.25K	0.01%	1136
2019 Q2	$249K	Sell	4,478 -600	-12%	-$31.3K	0.01%	1182
2019 Q1	$256K	Buy	5,078 +60	+1%	+$2.67K	0.01%	1194
2018 Q4	$202K	Buy	5,018 +1,430	+40%	+$73.7K	0.01%	1296
2018 Q3	$249K	Buy	3,588 +270	+8%	+$20.5K	0.01%	1426
2018 Q2	$251K	Buy	+3,318	New	+$209K	0.01%	1423

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Crossmark Global Holdings's EGRX Position: Q4 2020 in Review

Crossmark Global Holdings sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2020, closing a stake of 5,428 shares — an estimated $231K sold.

Crossmark Global Holdings first reported a position in EGRX in Q2 2018 and held it in 10 quarters. The position peaked at $285K in Q4 2019. 166 funds tracked by Wall St. Rank hold EGRX as of Q4 2020.

Crossmark Global Holdings reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Crossmark Global Holdings sold 5,428 Eagle Pharmaceuticals, Inc. shares in Q4 2020, an estimated $231K.
Crossmark Global Holdings first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2018 and held it in 10 quarters.
Crossmark Global Holdings's Eagle Pharmaceuticals, Inc. position peaked at $285K in Q4 2019.
166 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2020.

Based on Crossmark Global Holdings's 13F filing for Q4 2020, filed 14 Jan 2021.